Sinovac Biotech (SVA) Commences Timely Phase II Clinical Trial for EV71 Vaccine Candidate
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced it has initiated the phase II clinical trial for its proprietary inactivated vaccine against Hand, Foot and Mouth Disease (HFMD), which is caused by EV71. More than 90 percent of the reported cases of HFMD are reported in children age five and under. Though the disease is common and generally mild in severity, the company notes that in severe cases, HFMD is associated with neurological symptoms caused by EV71. In the company’s phase I trial, completed in May 2011, the company’s EV71 vaccine demonstrated good safety and…